(R)-Metoprolol

(R)-Metoprolol

SCHEMBL40918

COCCc1ccc(OC[C@H](O)CNC(C)C)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1

The experimentally established mechanism targets of (R)-Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 known ✓ P08588 4/20 1.00
ADRB2 P07550 3/20 1.00
CYP2D6 P10635 2/20 1.00
NR3C1 P04150 1/20 1.00
ADRA1A P35348 1/20 1.00
CYP2J2 P51589 1/20 1.00
PDE4D Q08499 1/20 1.00
NPY1R P25929 1/20 0.84
NPY2R P49146 1/20 0.84
PMP22 Q01453 1/20 0.84
NPSR1 Q6W5P4 1/20 0.84
TDP1 Q9NUW8 1/20 0.84
LMNA P02545 2/20 0.68
MEN1 O00255 1/20 0.68
CYP1A2 P05177 1/20 0.68
CYP2C9 P11712 1/20 0.68
KMT2A Q03164 1/20 0.68
GAA P10253 1/20 0.67
BLM P54132 1/20 0.67
TMEM97 Q5BJF2 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(S)-Metoprolol SCHEMBL121589 1.00 ADRB1 (1.00) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL1561123 1.00 ADRB1 (1.00) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL4093 1.00 ADRB1 (1.00) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL28445291 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
(S)-Metoprolol SCHEMBL2638035 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL6126034 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
(S)-Metoprolol SCHEMBL6728301 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL2638034 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL27911917 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL613509 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 12004 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260047897-A1 TECHNICAL AND THEORETICAL SPECIFICATIONS FOR SMALL-SCALE MACHINES AND MICRO-ROBOTS FOR DESTROYING ANY HARMFUL MATTER INSIDE A LIVING ORGANISM USING A SUPERCRITICAL FLUID HOFFMAN JASON (US) 2026-02-19 US claimed
EP-4691556-A2 HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF H. Lundbeck A/S (DK) 2026-02-11 EP claimed
US-20250382291-A1 SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS UNIV COLUMBIA (US) 2025-12-18 US claimed
WO-2025245481-A1 METHODS AND MATERIALS FOR TREATING CARDIAC CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-27 WO claimed
US-20250302887-A1 AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE AOBIOME LLC (US) 2025-10-02 US claimed
EP-4615449-A1 METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS Weinberg, Assa (US) 2025-09-17 EP claimed
US-12403262-B2 Tamper evident assembly with RFID for syringes FRESENIUS KABI USA, LLC (US) 2025-09-02 US claimed
US-20250262195-A1 METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS WEINBERG ASSA (US) 2025-08-21 US claimed
US-20250264469-A1 METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME CHILDREN'S HOSPITAL MEDICAL CENTER 2025-08-21 US claimed
EP-4598526-A1 METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS Weinberg, Assa (US) 2025-08-13 EP claimed
EP-0293347-A1 Metoprolol succinate and pharmaceutical composition containing it Aktiebolaget Hässle (SE) 1988-11-30 EP claimed
US-4780318-A DIFFERENT SOLUBILITIES AT DIFFERENT PHS LEJUS MEDICAL AKTIEBOLAG (SE) 1988-10-25 US claimed
CN-87101837-A The method and apparatus of granulating and one-tenth granule product thereof 1987-12-02 CN claimed
WO-1987005561-A1 METHOD AND APPARATUS FOR GRANULATION AND GRANULATED PRODUCT WASHINGTON UNIVERSITY TECHNOLOGY ASSOCIATES, INC. (US) 1987-09-24 WO claimed
EP-0237345-A2 Method and apparatus for granulation and granulated product WASHINGTON UNIVERSITY TECHNOLOGY ASSOCIATES, INC. (US) 1987-09-16 EP claimed
EP-0189861-A2 Percutaneous absorption accelerator for ionic water-soluble medicine SHOWA DENKO KABUSHIKI KAISHA (JP) 1986-08-06 EP claimed
EP-0079522-B1 N-CARBOXYMETHYL(AMIDINO)LYSYL-PROLINE ANTIHYPERTENSIVE AGENTS MERCK & CO. INC. (US) 1986-05-07 EP claimed
EP-0046289-B1 SUBSTITUTED ENANTHOLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, A PROCESS FOR PREPARING AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES MERCK & CO. INC. (US) 1985-11-27 EP claimed
EP-0148811-A1 Pharmaceutical composition LEJUS MEDICAL AKTIEBOLAG (SE) 1985-07-17 EP claimed
US-4281654-A Drug delivery system for controlled ocular therapy ALZA CORPORATION (US) 1981-08-04 US claimed